Search

Your search keyword '"Wagner, John L"' showing total 126 results
Start Over Author "Wagner, John L" Publication Type Academic Journals
126 results on '"Wagner, John L"'

2. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.

Published
2023
Full Text
View/download PDF

3. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Author

Murthy, Hemant S., Zhang, Mei-Jie, Chen, Karen, Ahmed, Sairah, Deotare, Uday, Ganguly, Siddhartha, Kansagra, Ankit, Michelis, Fotios V., Nishihori, Taiga, Patnaik, Mrinal, Abid, Muhammad Bilal, Aljurf, Mahmoud, Arai, Yasuyuki, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Martino, Rodrigo, Cahn, Jean-Yves, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Daly, Andrew, Dholaria, Bhagirathbhai, Diaz Perez, Miguel Angel, Freytes, César O., Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Jamy, Omer, Joseph, Jacinth, Kanakry, Christopher G., Khera, Nandita, Krem, Maxwell M., Kuwatsuka, Yachiyo, Lazarus, Hillard M., Lekakis, Lazaros J., Liu, Hongtao, Modi, Dipenkumar, Munshi, Pashna N., Mussetti, Alberto, Palmisiano, Neil, Patel, Sagar S., Rizzieri, David A., Seo, Sachiko, Shah, Mithun Vinod, Sharma, Akshay, Sohl, Melhm, Solomon, Scott R., Ulrickson, Matthew, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wang, Trent, Wirk, Baldeep, Zeidan, Amer, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Weisdorf, Daniel J., Saber, Wael, and Kharfan-Dabaja, Mohamed A.

Published
2023
Full Text
View/download PDF

6. A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose.

Author

Jeurkar, Chetan, Leiby, Benjamin, Rashid, Shaik, Gergis, Usama, Grossso, Dolores, Carabasi, Matthew, Filicko‐O'Hara, Joanne, O'Hara, William, Klumpp, Thomas, Porcu, Pierluigi, Flomenberg, Neal, and Wagner, John L.

Abstract

Posttransplant cyclophosphamide (PtCy) has been shown to decrease post‐hematopoietic stem cell transplant acute and chronic graft‐versus‐host disease (GVHD). In this study, PtCy was used in 44 patients along with mycophenolate and tacrolimus with HLA matched (29) and mismatched (15) unrelated donors to determine the impact of graft content on outcome; thus, all patients had flow cytometric analysis of their graft content including the number of B cells, NK cells, and various T cell subsets. Higher γδ T cell dose was associated with the development of acute GVHD (p =.0038). For PtCy, further studies of the cell product along with further graft manipulation, such as selective γδ T cell depletion, could potentially improve outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.

Published
2023
Full Text
View/download PDF

8. Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes

Author

Grosso, Dolores, Carabasi, Matthew, Filicko-O'Hara, Joanne, Wagner, John L., O'Hara, William, Sun, Michael, Colombe, Beth, Shi, W., Werner-Wasik, Maria, Rudolph, Shannon, Alpdogan, Onder, Binder, Adam, Kasner, Margaret, Klumpp, Thomas, Martinez-Outschoorn, Ubaldo, Palmisiano, Neil, Wilde, Lindsay, Porcu, Pierluigi, Gergis, Usama, and Flomenberg, Neal

Published
2020
Full Text
View/download PDF

9. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

Author

Im, Annie, Rashidi, Armin, Wang, Tao, Hemmer, Michael, MacMillan, Margaret L., Pidala, Joseph, Jagasia, Madan, Pavletic, Steven, Majhail, Navneet S., Weisdorf, Daniel, Abdel-Azim, Hisham, Agrawal, Vaibhav, Al-Homsi, A. Samer, Aljurf, Mahmoud, Askar, Medhat, Auletta, Jeffery J., Bashey, Asad, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Choe, Hannah, Ciurea, Stefan, Daly, Andrew, Perez, Miguel Angel Diaz, Farhadfar, Nosha, Gadalla, Shahinaz M., Gale, Robert, Ganguly, Siddhartha, Gergis, Usama, Hanna, Rabi, Hematti, Peiman, Herzig, Roger, Hildebrandt, Gerhard C., Lad, Deepesh P., Lee, Catherine, Lehmann, Leslie, Lekakis, Lazaros, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Khandelwal, Pooja, Martino, Rodrigo, Murthy, Hemant S., Nishihori, Taiga, O'Brien, Tracey A., Olsson, Richard F., Patel, Sagar S., Perales, Miguel-Angel, Prestidge, Tim, Qayed, Muna, Romee, Rizwan, Schoemans, Hélène, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, Teshima, Takanori, Urbano-Ispizua, Alvaro, Van der Poel, Marjolein, Vij, Ravi, Wagner, John L., William, Basem, Wirk, Baldeep, Yared, Jean A., Spellman, Steve R., Arora, Mukta, and Hamilton, Betty K.

Published
2020
Full Text
View/download PDF

11. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

Author

Murthy, Hemant S., Ahn, Kwang Woo, Estrada-Merly, Noel, Alkhateeb, Hassan B., Bal, Susan, Kharfan-Dabaja, Mohamed A., Dholaria, Bhagirathbhai, Foss, Francine, Gowda, Lohith, Jagadeesh, Deepa, Sauter, Craig, Abid, Muhammad Bilal, Aljurf, Mahmoud, Awan, Farrukh T., Bacher, Ulrike, Badawy, Sherif M., Battiwalla, Minoo, Bredeson, Chris, Cerny, Jan, Chhabra, Saurabh, Deol, Abhinav, Diaz, Miguel Angel, Farhadfar, Nosha, Freytes, César, Gajewski, James, Gandhi, Manish J., Ganguly, Siddhartha, Grunwald, Michael R., Halter, Joerg, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Jimenez-Jimenez, Antonio Martin, Kalaycio, Matt, Kamble, Rammurti, Krem, Maxwell M., Lazarus, Hillard M., Lazaryan, Aleksandr, Maakaron, Joseph, Munshi, Pashna N., Munker, Reinhold, Nazha, Aziz, Nishihori, Taiga, Oluwole, Olalekan O., Ortí, Guillermo, Pan, Dorothy C., Patel, Sagar S., Pawarode, Attaphol, Rizzieri, David, Saba, Nakhle S., Savani, Bipin, Seo, Sachiko, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wirk, Baldeep, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, and Saber, Wael

Published
2022
Full Text
View/download PDF

13. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

Author

Metheny, Leland, Callander, Natalie S., Hall, Aric C., Zhang, Mei-Jei, Bo-Subait, Khalid, Wang, Hai-Lin, Agrawal, Vaibhav, Al-Homsi, A. Samer, Assal, Amer, Bacher, Ulrike, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Bredeson, Chris, Byrne, Michael, Cairo, Mitchell, Cerny, Jan, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Freytes, César O., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kanakry, Christopher G., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Lee, Jong Wook, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Ringdén, Olov, Rizzieri, David, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Yared, Jean A., Hourigan, Christopher S., Kebriaei, Partow, Litzow, Mark, Sandmaier, Brenda M., Saber, Wael, Weisdorf, Daniel, and de Lima, Marcos

Published
2021
Full Text
View/download PDF

15. Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden

Author

Cornell, Robert F., Fraser, Raphael, Costa, Luciano, Goodman, Stacey, Estrada-Merly, Noel, Lee, Cindy, Hildebrandt, Gerhard, Gergis, Usama, Farhadfar, Nosha, Freytes, César O., Kamble, Rammurti T., Krem, Maxwell, Kyle, Robert A., Lazarus, Hillard M., Marks, David I., Meehan, Kenneth, Patel, Sagar S., Ramanathan, Muthalagu, Olsson, Richard F., Wagner, John L., Kumar, Shaji, Qazilbash, Muzaffar H., Shah, Ninah, Hari, Parameswaran, and D'Souza, Anita

Published
2021
Full Text
View/download PDF

17. A Two-Step Approach to Myeloablative Haploidentical Transplantation: Low Nonrelapse Mortality and High Survival Confirmed in Patients with Earlier Stage Disease

Author

Grosso, Dolores, Gaballa, Sameh, Alpdogan, Onder, Carabasi, Matthew, Filicko-O’Hara, Joanne, Kasner, Margaret, Martinez-Outschoorn, Ubaldo, Wagner, John L., O'Hara, William, Rudolph, Shannon, Chervoneva, Inna, Colombe, Beth, Farley, Patricia Cornett, Flomenberg, Phyllis, Pro, Barbara, Sharma, Manish, Shi, Wenyin, Weiss, Mark, and Flomenberg, Neal

Published
2015
Full Text
View/download PDF

27. Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

Author

Pan, Jonathan, Ghimire, Sushil, Alpdogan, S. Onder, Chapman, Andrew, Carabasi, Matthew, DiMeglio, Martina, Gong, Jerald, Martinez-Outschoorn, Ubaldo, Rose, Lewis, Ramirez, Michael, Wagner, John L., Weiss, Mark, Flomenberg, Neal, Pro, Barbara, Porcu, Pierluigi, Filicko-OHara, Joanne, and Gaballa, Sameh

Subjects
STEM cell transplantation, ETOPOSIDE, CARBOPLATIN, NON-Hodgkin's lymphoma
Abstract

We developed an outpatient salvage chemotherapy regimen using bendamustine, ofatumumab, carboplatin and etoposide (BOCE) to treat relapsed/refractory non-Hodgkin lymphoma (RR NHL) in a single-center phase I/II study. Primary objectives were safety, tolerability and overall response rate (ORR). Thirty-five RR NHL patients (57% de novo large cell [DLBCL] or grade 3B follicular [FL], 26% transformed DLBCL, 9% grade 3A FL, 3% mantle cell; median age = 62, median prior therapies = 1) were treated. Median follow-up was 24.1 months. ORR was 69% (CR = 49%, PR = 20% [ORR = 70%, CR = 50%, PR = 20% in the de novo DLBCL/grade 3B FL subgroup]). Median progression-free survival was 5.1 months and overall-survival 26.2 months. Twelve patients subsequently underwent stem cell transplantation. The most common non-hematologic grade 3–4 toxicities were neutropenic fever and hypophosphatemia. There were no treatment-related deaths. In conclusion, BOCE is a safe and effective outpatient salvage regimen for patients with RR NHL and serves as an effective bridge to stem cell transplantation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

28. Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Author

Park, Jae H, Nikiforow, Sarah, Kim, Soyoung, Hu, Zhen-Huan, Moskop, Amy, Ahmed, Sairah, Bilal Abid, Muhammad, Badar, Talha, Bredeson, Christopher, Brown, Valerie, Cairo, Mitchell S., Díaz, Miguel, Dholaria, Bhagirathbhai, Ganguly, Siddhartha, Grover, Natalie S, Hanna, Rabi, Hematti, Peiman, Kohorst, Mira A, Lazarus, Hillard, Lekakis, Lazaros J., Locke, Frederick L., Murthy, Hemant S., Mussetti, Alberto, Pulsipher, Michael A., Qayed, Muna, Reshef, Ran, Rizzieri, David A, Queralt Salas, Maria, Savani, Bipin B., Sharma, Akshay, Schultz, Kirk R., Thakar, Monica, Turtle, Cameron, Yared, Jean A., Wagner, John L., Qiu, Xianmiao, Pasquini, Marcelo C, and Perales, Miguel-Angel

Published
2021
Full Text
View/download PDF

29. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

Author

McSweeney, Peter A., Niederwieser, Dietger, Shizuru, Judith A., Sandmaier, Brenda M., Molina, Arthur J., Maloney, David G., Chauncey, Thomas R., Gooley, Theodore A., Hegenbart, Ute, Nash, Richard A., Radich, Jerald, Wagner, John L., Minor, Steven, Appelbaum, Frederick R., Bensinger, William I., Bryant, Eileen, Flowers, Mary E.D., Georges, George E., Grumet, F. Carl, Kiem, Hans-Peter, Torok-Storb, Beverly, Yu, Cong, Blume, Karl G., and Storb, Rainer F.

Published
2001
Full Text
View/download PDF

33. Vaccination Response after Autologous Stem Cell Transplantation

Author

Alpdogan, Onder, Hong, Jennifer, Klumpp, Thomas R., Abdulkareem, Abdullateef O, Binder, Adam F., Carabasi, Matthew, Filicko-O'Hara, Joanne, Grosso, Dolores, Kasner, Margaret, Martinez-Outschoorn, Ubaldo, Palmisiano, Neil, Wilde, Lindsay, Porcu, Pierluigi, Gergis, Usama, Wagner, John L., and Flomenberg, Neal

Published
2020
Full Text
View/download PDF

39. The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With Increased Survival in CMV Positive Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation.

Author

Grosso, Dolores, Leiby, Benjamin, Carabasi, Matthew, Filicko-O'Hara, Joanne, Gaballa, Sameh, O'Hara, William, Wagner, John L., and Flomenberg, Neal

Subjects
HEMATOPOIETIC stem cell transplantation, ALLELES, HLA histocompatibility antigens, LYMPHOCYTE count, GRAFT versus host disease
Abstract

Specific major histocompatibility (MHC) class I alleles dominate anti-CMV responses in a hierarchal manner. These CMV immunodominant (IMD) alleles are associated with a higher magnitude and frequency of cytotoxic lymphocyte responses as compared to other human leukocyte antigen (HLA) alleles. CMV reactivation has been associated with an increased incidence of graft-vs.-host disease and non-relapse mortality, as well as protection from relapse in HLA-matched HSCT settings. Less is known about the impact of CMV reactivation on these major outcomes after haploidentical (HI) HSCT, an increasingly applied therapeutic option. In HI HSCT, the efficiency of the immune response is decreased due to the immune suppression required to cross the MHC barrier as well as MHC mismatch between presenting and responding cells. We hypothesized that the presence of a CMV IMD allele would increase the efficiency of CMV responses after HI HSCT potentially impacting CMV-related outcomes. In this retrospective, multivariable review of 216 HI HSCT patients, we found that CMV+ recipients possessing at least 1 of 5 identified CMV IMD alleles had a lower hazard of death (HR = 0.40, p = 0.003) compared to CMV+ recipients not possessing a CMV IMD allele, and an overall survival rate similar to their CMV– counterparts. The analysis delineated subgroups within the CMV+ population at greater risk for death due to CMV reactivation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Author

Pan, Jonathan, Ghimire, Sushil, Zhan, Tingting, Alpdogan, Onder, Chapman, Andrew E., Carabasi, Matthew, Martinez-Outschoorn, Ubaldo, Rose, Lewis J., Ramirez, Michael, Wagner, John L, Pro, Barbara, Weiss, Mark A., Flomenberg, Neal, Porcu, Pierluigi, Filicko-O'Hara, Joanne, and Gaballa, Sameh

Published
2019
Full Text
View/download PDF

44. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Author

Kasner, Margaret T., Mick, Rosemarie, Jeschke, Grace R., Carabasi, Matthew, Filicko-O’Hara, Joanne, Flomenberg, Neal, Frey, Noelle V., Hexner, Elizabeth O., Luger, Selina M., Loren, Alison W., Mangan, James K., Wagner, John L., Weiss, Mark, Carroll, Martin, and Perl, Alexander E.

Subjects
FLOW cytometry, ETOPOSIDE, RAPAMYCIN, CLINICAL trials, MITOXANTRONE, CONFIDENCE intervals, FORMALDEHYDE, CANCER chemotherapy, MYELOID leukemia, TREATMENT effectiveness, SPONTANEOUS cancer regression, CYTARABINE, PHOSPHORYLATION, DRUG toxicity, DISEASE risk factors
Abstract

Background Mammalian Target of Rapamycin Complex 1 (mTORC1) inhibitors enhance chemotherapy response in acute myelogenous leukemia (AML) cells in vitro. However whether inhibiting mTORC1 enhances clinical response to AML chemotherapy remains controversial. We previously optimized measurement of mTORC1’s kinase activity in AML blasts during clinical trials using serial phospho-specific flow cytometry of formaldehyde-fixed whole blood or marrow specimens. To validate mTORC1 as a therapeutic target in AML, we performed two clinical trials combining an mTORC1 inhibitor (sirolimus) and MEC (mitoxantrone, etoposide, cytarabine) in patients with relapsed, refractory, or untreated high-risk AML. Methods Flow cytometric measurements of ribosomal protein S6 phosphorylation (pS6) were performed before and during sirolimus treatment to determine whether mTORC1 inhibition enriched for chemotherapy response. Results In 51 evaluable subjects, the overall response rate (ORR) to the combination regimen was 47% (95% confidence interval 33-61%, 33% CR, 2% CRi, 12% PR) and similar toxicity to historic experience with MEC alone. 37 subjects had baseline pS6 measured pre-sirolimus, of whom 27 (73%) exhibited mTORC1 activity. ORR was not significantly different between subjects with and without baseline mTORC1 activity (52% vs 40%, respectively, p = 0.20). The ORR among subjects with baseline target activation and mTORC1 inhibition during therapy was 71% (12/17) compared to 20% (2/10) in subjects without target inhibition. Conclusions Fixed, whole blood pS6 by flow cytometry may be a predictive biomarker for clinical response to mTORC1 inhibitor-based regimens. These data provide clinical confirmation that mTORC1 activation mediates chemotherapy resistance in patients with AML. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

48. Smoking History and Pre-Transplant Pulmonary Function Predict Post-Transplant Respiratory Failure, Acute Renal Failure Requiring Dialysis and 100-Day Mortality in Allogeneic Bone Marrow Transplantation

Author

Mikkilineni, Lekha, Parikh, Kinjal, Martin, Fern, Grosso, Dolores, Leiby, Benjamin, Alpdogan, Onder, Carabasi, Matthew, Kasner, Margaret, Klumpp, Thomas R., Martinez-Outschoorn, Ubaldo, Sharma, Manish, Weiss, Mark, Wagner, John L., Flomenberg, Neal, and Filicko-O'Hara, Joanne E.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results